• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Suez Canal University Medical Journal
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 28 (2025)
Volume Volume 27 (2024)
Issue Issue 12
Issue Issue 11
Issue Issue 10
Issue Issue 9
Issue Issue 8
Issue Issue 7
Issue Issue 6
Issue Issue 5
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 26 (2023)
Volume Volume 25 (2022)
Volume Volume 24 (2021)
Volume Volume 23 (2020)
Volume Volume 22 (2019)
Volume Volume 21 (2018)
Volume Volume 20 (2017)
Volume Volume 19 (2016)
Volume Volume 18 (2015)
Volume Volume 17 (2014)
Volume Volume 16 (2013)
Volume Volume 15 (2012)
Volume Volume 14 (2011)
Volume Volume 13 (2010)
Khalil, F., Mohamed, M., Salem, N., Ali, E. (2024). Assessment of Serum Interleukin-6 as a Reliable Biomarker for Disease Activity in Ulcerative Colitis. Suez Canal University Medical Journal, 27(12), 7-14. doi: 10.21608/scumj.2024.440467
fawzy A. Khalil; Mohamed A. Mohamed; Naglaa E. Salem; Esraa A. Ali. "Assessment of Serum Interleukin-6 as a Reliable Biomarker for Disease Activity in Ulcerative Colitis". Suez Canal University Medical Journal, 27, 12, 2024, 7-14. doi: 10.21608/scumj.2024.440467
Khalil, F., Mohamed, M., Salem, N., Ali, E. (2024). 'Assessment of Serum Interleukin-6 as a Reliable Biomarker for Disease Activity in Ulcerative Colitis', Suez Canal University Medical Journal, 27(12), pp. 7-14. doi: 10.21608/scumj.2024.440467
Khalil, F., Mohamed, M., Salem, N., Ali, E. Assessment of Serum Interleukin-6 as a Reliable Biomarker for Disease Activity in Ulcerative Colitis. Suez Canal University Medical Journal, 2024; 27(12): 7-14. doi: 10.21608/scumj.2024.440467

Assessment of Serum Interleukin-6 as a Reliable Biomarker for Disease Activity in Ulcerative Colitis

Article 2, Volume 27, Issue 12, December 2024, Page 7-14  XML PDF (315.86 K)
Document Type: Original Article
DOI: 10.21608/scumj.2024.440467
View on SCiNiTO View on SCiNiTO
Authors
fawzy A. Khalil1; Mohamed A. Mohamed2; Naglaa E. Salem3; Esraa A. Ali email 4
1Gastroenterology and Hepatology, Faculty of medicine, Suez Canal University, Ismailia, Egypt
2Internal Medicine, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
3Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
4Gastroenterology and Hepatology, Faculty of medicine, Suez Canal University, Ismailia, Egypt.
Abstract
Background: A chronic idiopathic inflammatory bowel disease of the colon, ulcerative colitis produces varied degrees of mucosal inflammation that extends from the rectum to the more proximal colon. Genetics, environmental factors, autoimmune, and gut microbiota are the main risk factors for ulcerative colitis. The diagnosis of Ulcerative Colitis is made using a combination of histology, endoscopic results, and clinical presentation. In addition to confirming the diagnosis of UC. There is significant evidence that UC patients' blood and inflamed mucosa have higher levels of interleukin-6. Aim:To establish new non-invasive alternatives for monitoring the disease activity in patients with ulcerative colitis. Subjects and Methods: Analytical cross-sectional study was conducted among 42 patients with known or newly diagnosed UC who was presented to the out-patient clinic or admit at the Suez Canal University hospital, Ismailia, Egypt. The diagnosis of UC was based on clinical, endoscopic, and histological criteria.  Results: our study demonstrated that more than half of patients (52.4%) had moderately active UC, (28.6%) had severely active and about (14.3%) had mild activity when patients assessed clinically by P Mayo score with significant correlation between the circulating IL-6 level and UC activity in the studied patients (P value <0.001), the mean value of IL-6 was double higher in patients with moderate-severe activity compared to those with remission/mild activity (153 vs. 76 pg/ml). Conclusion: Our study concluded that IL-6 can be used as a significant biomarker for both disease activity, severity and extension by colonoscopy in patients with ulcerative colitis.
Keywords
Inflammatory Bowel Disease; Disease Activity; Severity; Patient; Colonoscopy
Main Subjects
Clinical Research (Medical)
Statistics
Article View: 36
PDF Download: 22
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.